Αρχική World News Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2... World News Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements Από Ogkologos - 11 Ιουνίου, 2026 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cancer in My Community: Overcoming Delays in Care for Children With... 6 Ιουλίου, 2023 Genetic Counseling for Hereditary Breast Cancer: What People With a Family... 26 Οκτωβρίου, 2023 Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality... 10 Νοεμβρίου, 2023 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... 15 Νοεμβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target... Embedding research integrity at the core of our science Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... Reunión anual de la American Society of Clinical Oncology de 2023:...